Literature DB >> 22172095

Clinical practice of image-guided spine radiosurgery--results from an international research consortium.

Matthias Guckenberger1, Reinhart A Sweeney, John C Flickinger, Peter C Gerszten, Ronald Kersh, Jason Sheehan, Arjun Sahgal.   

Abstract

BACKGROUND: Spinal radiosurgery is a quickly evolving technique in the radiotherapy and neurosurgical communities. However, the methods of spine radiosurgery have not been standardized. This article describes the results of a survey about the methods of spine radiosurgery at five international institutions.
METHODS: All institutions are members of the Elekta Spine Radiosurgery Research Consortium and have a dedicated research and clinical focus on image-guided radiosurgery. The questionnaire consisted of 75 items covering all major steps of spine radiosurgery.
RESULTS: Strong agreement in the methods of spine radiosurgery was observed. In particular, similarities were observed with safety and quality assurance playing an important role in the methods of all institutions, cooperation between neurosurgeons and radiation oncologists in case selection, dedicated imaging for target- and organ-at-risk delineation, application of proper safety margins for the target volume and organs-at-risk, conformal planning and precise image-guided treatment delivery, and close clinical and radiological follow-up. In contrast, three major areas of uncertainty and disagreement were identified: 1) Indications and contra-indications for spine radiosurgery; 2) treatment dose and fractionation and 3) tolerance dose of the spinal cord.
CONCLUSIONS: Results of this study reflect the current practice of spine radiosurgery in large academic centers. Despite close agreement was observed in many steps of spine radiosurgery, further research in form of retrospective and especially prospective studies is required to refine the details of spinal radiosurgery in terms of safety and efficacy.
© 2011 Guckenberger et al; licensee BioMed Central Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22172095      PMCID: PMC3286433          DOI: 10.1186/1748-717X-6-172

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


Background

Radiotherapy is a well-established treatment for painful vertebral metastases. Multiple prospective studies report pain response rates of 50 to 90% [1-4]. Based on randomized studies, no differences in pain response have been observed between the various fractionation schemes that range from 40 Gy in 20 fractions to 8 Gy in a single fraction [5,6]. Despite the lack of a dose response relationship for pain control, there is good rationale for high dose escalation beyond those conventional dose levels tested with the aim to improve upon existing rates of local and pain control. The median duration of pain response after conventional palliative radiotherapy is approximately 3 to 6 months, again without differences between the different fractionation schemes [1-4]. Only short palliation after conventional radiotherapy seems to be the case especially for unfavorable histologies (lung, kidney, head & neck and gastrointestinal cancer, melanoma, sarcoma) as observed in a randomized trial for metastatic spinal cord compression [7]. This brief palliative effect may be sufficient for some patients with very short life expectancy. However, several predictive scores have been reported, which allow selection of patients with long life expectancy [8-10]. In particular, as modern chemotherapy may further prolong life expectancy, long-term palliation and long-term tumor control become even more important goals for patients despite having metastatic disease. As a consequence, there is currently large interest in intensification of radiotherapy for painful vertebral metastases. A recent survey from the Unites States reported that 64% of the radiation oncologists practice stereotactic body radiotherapy (SBRT) and treatment of vertebral metastases was the second most common disease site (67.5% of all SBRT users) [11]. Spine SBRT was practiced most frequently as single fraction radiosurgery with doses of 20 Gy or 18 Gy. The most frequently cited reasons for practice of SBRT were the possibility of dose-intensified treatment and re-irradiation. In the remainder of this manuscript, we will use the term radiosurgery for both single-fraction and multiple-fraction SBRT as the techniques of the entire treatment processes are identical between both. Multiple retrospective and few prospective studies have reported promising results for spine radiosurgery with low rates of toxicity and pain control as well as local tumor control rates consistently ranging between 70 - 90% [12-18]. Importantly, the risk of permanent spinal cord damage secondary to radiation induced myelopathy has been reported as very low. Despite these promising data, recent reviews have pointed out the lack of uniformity in practice [19-21], and currently the community has no standard approach to the practice of spine radiosurgery. For example, there is variability in the treatment techniques, the total dose prescribed to the tumor, number of fractions, criteria for plan acceptance and the dose limits used to the organs at risk. One recent advance in providing guidance and uniformity to the practice of spine radiosurgery has been the RTOG phase II/III trial that is currently accruing in the US (RTOG 0631); however, results of this trial will not be available in the near future. The purpose of our study is to give a broad and comprehensive overview of the current methods of spine radiosurgery by surveying experienced practitioners. Five institutions, all members of the international Elekta Spine Radiosurgery Research Consortium, answered a questionnaire with detailed questions about all steps of spine radiosurgery from indication to follow-up. All centers used identical equipment for treatment delivery (Elekta Synergy S linacs all equipped with cone-beam and robotic HexaPOD technology), which facilitates methods comparison between the institutions.

Methods

The Elekta Spine Radiosurgery Research Consortium (ESRRC) is an international research consortium consisting of five institutions, all of them with a research and clinical focus on image-guided high precision radiotherapy in general and spine radiosurgery in particular. Four of five institutions are academic hospitals (University Hospital Wuerzburg [UHW], Wuerzburg, Germany; Princess Margaret Hospital (PMH) and the Sunnybrook Health Sciences Center (SHSC) of the University of Toronto [UofT], Toronto, Canada; University of Pittsburgh Medical Center [UPMC], Pittsburgh, US; University of Virginia Medical Center [UVAMC], Charlottesville, US) and one is a private radiotherapy center fully specialized in image-guided radiosurgery (Riverside Regional Medical Center [RSMC], Newport News, US). All institutions have treated more than 50 patients with vertebral metastases using image-guided radiosurgery and all academic centers have contributed to the recent technical and clinical progress in spine SBRT. Each center uses identical equipment for delivery of spine radiosurgery: treatment is planned for a high-resolution multi-leaf collimator with 4 mm leaf width (Beam modulator on Elekta Synergy S linear accelerator; Elekta, Crawley, UK), daily volumetric image-guidance is performed with cone-beam technology (Elekta XVI, Crawley, UK), set-up errors are corrected in six degrees of freedom (HexaPOD; Medical Intelligence, Schwabmuenchen) and all patients are immobilized in the BodyFIX system (Medical Intelligence, Schwabmuenchen, Germany). A questionnaire with 75 items was established covering all major aspects of spine radiosurgery including: indications for spine radiosurgery, imaging required for treatment planning, target and organ-at-risk (OAR) definition, treatment planning, dose and fractionation, tolerance doses for OARs, patient positioning and image-guidance, follow-up and response evaluation. Re-irradiation and post-operative radiosurgery was not evaluated in this questionnaire. The questionnaires were answered by the responsible physician from each institution and reflect their current practice of spinal radiosurgery.

Results

Indication for spine radiosurgery

Rationales for the practice of spine radiosurgery compared to conventional palliative radiotherapy are similar between the five institutions: all agree on more durable pain control and long-term local tumor control. Four institutions state a more rapid pain relief as reason for spine radiosurgery (UPMC, UofT, UVAMC, RSMC), three institutions explicitly mention spine radiosurgery for radio-resistant histologies (UHW, UVAMC, UofT), two institutions use spine radiosurgery because of better patient convenience (UPMC, RSMC) and one institution describes the potential of improved overall survival in the oligometastatic setting as reason for spine radiosurgery (UHW). Radiosensitive histologies are excluded in all but one (RSMC) institution and a minimum performance status is required in all institutions (table 1). All four academic centers perform spine radiosurgery in the framework of a prospective protocol but not as a prospective trial.
Table 1

Patient specific factors influencing indication for spine SBRT

UHWUPMCUofTUVAMCRSMC
Use of a predictive scoring system for OSYes, Mizumoto ScoreNoLife expectancy ≥ 3 monthsPatients with widespread CNS and systemic disease are excludedNo

Histology of primary tumorNo treatment of highly radiosensitive histologiesAvoid relatively radiosensitive histologiesNo myeloma unless previously radiatedNo treatment of radiosensitive histologiesNo relevant factor

Status of primary tumorYes, part of the Mizumoto ScoreNo relevant factorYes, for estimation of life expectancyNo relevant factorNo relevant factor

Presence of visceral metastasesYes, part of the Mizumoto ScoreNo relevant factorYes, for estimation of life expectancyYes, see aboveNo relevant factor

AgeYes, part of the Mizumoto ScoreNo relevant factorNo relevant factorNo relevant factorNo relevant factor

Performance status of patientYes, part of the Mizumoto ScoreExclusion of patients with extremely poor performance statusMust be able to tolerate immobilization for 45 min.KPS should be ≥70KPS must be ≥60

Comorbidities of patientNo relevant factorNo relevant factorNo relevant factorNo relevant factorNo relevant factor

Interval between primary tumor and spinal metastasesNo relevant factorNo relevant factorNo relevant factorNo relevant factorNo relevant factor
Patient specific factors influencing indication for spine SBRT In contrast, patient selection with respect to estimated live expectancy is substantially different: one institution strictly selects patients with good life expectancy using a predictive scoring system for overall survival (UHW), two centers exclude patients with very poor life expectancy (UofT, UVAMC) and life expectancy is no relevant factor for two institutions (UPMC, RSMC).

Characteristics of metastatic lesions treated with spine radiosurgery

The inclusion and exclusion criteria of vertebral metastasis treated with spine radiosurgery are described in table 2. There is agreement that the relationship between the target volume and any OAR other than the spinal cord does not influence the indication for spine radiosurgery. Both lytic and sclerotic lesions are treated and all institutions but one (UHW) prefer a stabilization procedure prior to radiosurgery in cases of spinal instability. Compression fractures are always discussed with the neurosurgeon/spine surgeon and symptomatic spinal cord compression is a contraindication in all institutions. All vertebras in the cervical, thoracic and lumbar spine are treated and the number of vertebras within one target volume is limited to 3 except one institution, were only two vertebras are allowed within one target volume (RSMC).
Table 2

Target specific factors influencing indication for spine SBRT

UHWUPMCUofTUVAMCRSMC
Location of vertebral metastases (C, T, L)No relevant factorNo relevant factorNo relevant factorNo relevant factorNo relevant factor

Number of vertebras in one target volumeMaximum of 3 levelsMaximum of 3 levelsMaximum of 3 levelsMaximum of 3 levelsMaximum of 2 levels

Extent of vertebral metastasesSymptomatic and progressive cord compression is contraindication.Significant spinal cord compression associated with myelopathy is contraindication.Symptomatic cord compression is contraindication.Symptomatic cord compression is contraindication.Symptomatic cord compression is contraindication.

Epidural involvementNo relevant factorNo relevant factorSurgery if high grade epidural involvement presentMinimum of 2 mm of clearance between the gross metastastic disease and the spinal cordNo relevant factor

Stability of metastatic vertebraSurgical opinion sought firstInstability is preferably treated with stabilization procedureSurgical opinion sought firstInstability is preferably treated with stabilization procedureInstability is preferably treated with stabilization procedure

Lytic or sclerotic metastasisNo relevant factorNo relevant factorNo relevant factorNo relevant factorNo relevant factor

Vertebral compression fractureSymptomatic compression fracture are discussed with neurosurgeons in advanceCompression fracture causing kyphosis and pain will be treated BEFORE radiosurgery if possibleSurgical opinion sought firstCompression fracture causing marked kyphosis or instability will be treated with stabilization procedure firstCompression fracture is preferably treated with stabilization procedure

Location of metastasis relative to other organs at riskNo relevant factorNo relevant factorNo relevant factorNo relevant factorNo relevant factor
Target specific factors influencing indication for spine SBRT Disagreement is evident whether epidural involvement or a small distance between the metastasis and the spinal cord are contraindications.

Imaging for staging and target definition

There is a good agreement in the imaging modalities and their technical application for staging and target definition (table 3). All institutions acquire dedicated CT and MRI images (a diagnostic MRI is allowed at the UPMC) for delineation and slice thickness is between 1-2 mm.
Table 3

Imaging for staging & target definition

UHWUPMCUofTUVAMCRSMC
Staging examinations prior to SBRT/SRSOncologic staging is requiredNoneMRI spineNoneNone

Slice thickness of Planning CT1.5 mm1.25 mm1 mm1 to 1.5 mm2 mm

MRI used for target definitionYesYesYesYesYes

Dedicated Planning MRIYesNoYesYesYes

Slice thickness of planning MRI2 mm1.25 mm1 mm1.2 mm3 mm/1.25 mm

MRI sequence used for target definition,T1 with and w/o contrast; T2T1 with contrast; T2T1 w/o contrast volumetric VIBE; T2 volumetric SPACET1 with contrast volume acquisitionT1 with and w/o

Dedicated FDG-PET/PET-CT for target definitionRarelyYesNoRarelyYes
Imaging for staging & target definition Differences, however, are observed in the MRI sequences and in acquisition of a dedicated planning FDG-PET.

Target and OAR definition

Similar target volume concepts are used in the five institutions (table 4). All centers define the gross-tumor volume (GTV) based on CT and MR imaging, two centers perform co-registration of a FDG-PET (UPMC, RSMC). All centers treat the involved vertebras only without "prophylactic" irradiation of the superior and inferior vertebra. All institutions use an anatomical target volume concept where the target volume extends to uninvolved parts of the vertebras. Additionally, all institutions but one (RSMC) apply safety margins of 2-3 mm.
Table 4

Target and organs-at-risk definition

UHWUPMCUofTUVAMCRSMC
Imaging modality, which is used for GTV definitionMRI and CTMRI and CT, FDG-PET if availableMRI and CTCT and MRICT, MRI and FDG-PET

Use of an anatomical target volume conceptAnatomical two dose-level target volume conceptAnatomical target volume conceptAnatomical target volume conceptAnatomical target volume conceptAnatomical target volume concept

GTV to PTV safety margin3 mm2 mm; 3 mm in the sacrum.2 mm2 mmNone

Protocol if PTV overlaps with the. spinal cordTwo dose-level approach;The OAR spinal cord is always in the PTV-elective and is always excluded from the higher dose PTV-macroscopicPTV within 1 mm to the spinal cord is excluded from the PTVPTV is limited by the cord or thecal sac for cauda equinaIf this occurs, we either operate to resect part of the tumor or fractionate the radiation.GTV drawn to edge of OAR

Treatment of the vertebra superior and inferior to the metastatic vertebraNoNoNoNoNo

Imaging modality for definition of the spinal cordSpinal cord in MRISpinal cord in MRISpinal cord in MRISpinal cord in MRISpinal canal in CT

Delineation of the spinal cord in cranio-caudal directionAt least 1 level above and below PTV1 level above and below PTVAt least 1 level above and below PTV1 level above and below PTV1 level above and below PTV

Safety margins around the spinal cord in axial directions1 mm1 mm1.5 mmNo2 mm anterior and 1 mm lateral

Delineation of the cauda equinaThecal sacThecal sacThecal sacThecal sacThecal sac

Delineation other OARs (e.g. kidney)No application of safety marginsNo application of safety marginsNo application of safety marginsNo application of safety marginsNo application of safety margins
Target and organs-at-risk definition However, the details of the target volume concepts are different. Three institutions do always treated the entire vertebral body and/or the entire posterior elements in case of involvement (UPMC, UVAMC, RSMC). One institution has a similar concept, however, differentiates between the ipsilateral and contralateral posterior elements (UofT). One institution uses a two dose level approach where the high-dose target volume is defined as the GTV with a 3 mm safety margin and the low-dose target volume is the entire vertebra (UHW). Regarding definition of the OAR spinal cord, all but one institution (RSMC) define the spinal cord in the MRI images; the spinal canal is delineated in CT images at the RSMC. Delineation is performed minimum 1 vertebra superior and inferior to the planning target volume (PTV) in all institutions and safety margins of 1-2 mm are applied for generation of the planning OAR spinal cord in all but one institution (UVAMC). On the level of the cauda equina, all institutions define the thecal sac as planning OAR.

Treatment dose and fractionation

Large variability is observed in terms of treatment dose and fractionation (tables 5). Two institutions treat the majority of their patients with single fraction radiosurgery of 16 - 24 Gy (UPMC, UVAMC). One center prefers 2 or 3 fraction radiosurgery (UofT), however, will treat with single fraction if no epidural disease is evident and single level disease. Two centers perform fractionated radiosurgery only (UHW, RSMC), and both of them choose between two fractionation schemas with estimated life expectancy as selection criterion. Fractionated radiosurgery is performed in 2-10 fractions with physical doses of 24 - 48.5 Gy. Despite the differences in dose and fractionation, all but one institution practice dose prescription to the D90, whereas one institution uses the ICRU reference point (UofT).
Table 5

Doses and fractionation

UHWUPMCUofTUVAMCRSMC
Use of single fraction radiosurgeryNo, all patients are treated with either five or ten fractionsSingle fraction radiosurgery for 95% of the patients unless very near to spinal cord.Majority is treated with two or three fractions and specific cases for single fractionMajority is treated with a single fraction of radiosurgery, occasionally up to 3 fractionsNo, majority are treated with three fractions with treatments given one week apart.

Criteria for selection of hypo-fractionated regimesSelection of fractionation scheme based on life expectancy using the Mizumoto ScoreFractionated protocols in:1. Epidural disease or large volume and no prior irradiation2. Prior radiationFractionated protocols after prior radiationIf it represents the only site of disease, we use 30 Gy in 3

Schema 1: # fractions and single fraction doseGood life expectancy:30 Gy in 10: PTV-elective48.5 Gy in 10: PTV -macroscopic *16-24 Gy in 1;Most frequently 17 Gy in 120-24 Gy in 1;Most frequently 20 Gy in 118 to 24 Gy in 1;Most frequently 20 Gy in 124 Gy in 3

Schema 2: # fractions and single fraction doseIntermediate life expectancy:20 Gy in 5: PTV-elective35 Gy in 5: PTV -macroscopic *24 - 27 Gy in 2-324 Gy in 330 Gy in 3

Schema 3: # fractions and single fraction dose30 Gy in 3(for sarcomas)18 Gy in 3

Dose prescriptionD90D90ICRU pointD90D90

* a simultaneous integrated boost (SIB) was used at the UHW with two dose levels to PTV -macroscopic and PTV -elective

Doses and fractionation * a simultaneous integrated boost (SIB) was used at the UHW with two dose levels to PTV -macroscopic and PTV -elective Based on an α/β = 10 Gy, the median 2 Gy-equivalent dose (EQD2 Gy) is 50 Gy [minimum 36 Gy (3 × 8 Gy) and maximum 68 Gy (1 × 24 Gy)]. As described above, one institution (UHW) uses a two dose-level concept with conventional doses in the "elective" parts of the vertebra (10 × 3 Gy; 5 × 4 Gy) and dose escalated irradiation in the involved parts of the vertebra (10 × 4.85 Gy; 5 × 7 Gy).

Spinal cord tolerance doses

No institution varies the spinal cord tolerance based on cervical, thoracic or lumbar target location. Otherwise, dosimetric parameters as well as tolerance doses for the spinal cord and thecal sac were substantially different between all five institutions (table 6).
Table 6

Spinal cord tolerance doses

Tolerance doses Spinal Cord
Dosimetric parameterSingle fraction3 fractions5 fractions10 fractions

UHWDmax to 0.1 cc23.75 Gy35 Gy

UPMCDmax11 Gy18 Gy

UofTDmax10 Gy17.5 Gy22 Gy

UVAMCD1010 Gy15 Gy20 Gy

RSMC2 cc18 Gy

Tolerance doses Cauda equina

Dosimetric parameterSingle fraction3 fractions5 fractions10 fractions

UHWDmax to 0.1 cc25 Gy37.5 Gy

UPMCDmax12 Gy18 Gy

UofTDmax12 Gy18 Gy23 Gy

UVAMCD1012 Gy15 Gy20 Gy

RSMC2 cc24 Gy
Spinal cord tolerance doses

Treatment planning

Minor differences are observed in terms of treatment planning (table 7). All institutions treat their patients at an Elekta Synergy S linear accelerator equipped with the Beam Modulator (4 mm leaf width); one center does also perform spine radiosurgery on different linear accelerators (UVAMC). Treatment planning system is Pinnacle (Philips Radiation Oncology Systems, Milpitas, CA, USA) and intensity modulation is planed using step-and-shoot IMRT only (UPMC), both IMRT and VMAT (UHW, RSMC, UofT) and VMAT only (UVAMC). Technical details are summarized in table 7.
Table 7

Treatment planning

UHWUPMCUofTUVAMCRSMC
Treatment planning systemPinnaclePinnaclePinnacleVarian Eclipse, Tomotherapy,Pinnacle for Elekta1. Elekta/CMS XiO,2. Elekta/CMS Monaco

Linac model/MLC leaf widthElekta Synergy S/4 mmSynergy S/4 mmElekta Synergy S/4 mmElekta Synergy S,Varian Triliogy,TomotherapyElekta Synergy S/4 mm

IMRT or VMAT treatment planningBothIMRTBothVMATBoth

If step-and-shoot IMRT: number of beams9 beams on average9 to 14, but most are 12 beams9 - 11 beams10 beams10 beams

If VMAT: number of arcs1-2 arcsNot applicable1 arc1-3 arcs1. one arc 120-140 segments2. VMAT - 4 arcs - 30-40 segments per arc

Full or partial VMAT arc360 degrees360 degrees360 degrees360 degree arcs1. VMAT 350 deg arc2. VMAT posteriorly biased arcs, 2 couch kicks

Photon energy6 or 10 mV depending on location6 MV6 MV6 MV6 MV

Dosimetric parameters for plan acceptanceNo strict acceptance criteria.Usually V90CTV V80 of at least 80-90%No strict acceptance criteriaGenerally D90
Treatment planning Acceptance criteria for treatment plans vary substantially with all centers stating that no strict criteria exist, mostly because of the large variability of the target volumes in terms of size, shape and distance to the spinal cord and other relevant OARs. However, all institutions agree that PTV coverage is sacrificed until the dose limits of the critical OARs, especially of the spinal cord, are fulfilled.

Patient positioning, immobilization and image-guidance

Differences in these steps of spine radiosurgery are small (table 8). All patients are treated in supine position and immobilization is performed using thermoplastic head masks for cervical/upper thoracic lesions and the BodyFIX for thoracic and lumbar lesions. Daily pre-treatment image guidance is performed using cone-beam technology and set-up errors are corrected in six degrees of freedom using the robotic HexaPOD couch. Action level for translational errors is 1 mm in all but one institution where a larger action level of 2 mm is used (UVAMC); the action level for rotational errors is 1° in four institutions (UHW, UPMC, UofT, UVAMC), 0.3° in one institution (RSMC). A second cone-beam CT scan for verification of the IGRT shift is performed in all institutions and all institutions but one (UHW) perform intra-treatment cone-beam CT scanning for patient monitoring. A final scan after treatment delivery is performed in 3/5 institutions (UHW, UofT, UVAMC).
Table 8

Patient (re-)positioning and IGRT

UHWUPMCUofTUVAMCRSMC
Treatment prone or supineSupineSupineSupinesupineSupine

Immobilization deviceCervical: Thermoplastic mask;otherwise BodyFIXCervical down to T5: aquaplast face mask;otherwise BodyFIXCervical down to T2/3 s frame;otherwise BodyFIXCervical: Thermoplastic mask;otherwise BodyFIXCervical: Aquaplast mask with Accuform support secured to modified S-frame;otherwise BodyFIX

Image guidance technologyCone-beam CTCone-beam CTCone-beam CTCone-beam CTCone-beam CT

Frequency of IGRTDailyDailyDailyDailyDaily

Correction of rotational set-up errorsYes - Hexapod couchYes - Hexapod couchYes - Hexapod couchYes - Hexapod couchYes - Hexapod couch

Action level for correction of set-up errors1 mm translation,1 degree rotation1 mm translation,1 degree rotation1 mm translation,1 degree rotation2 mm translation,1 degree rotation1 mm translation,0.3 degree rotation

Second imaging after couch adjustment prior to treatmentYesYesYesYesYes

Methods for intra-fractional patient monitoringNoneCone-beam CT imaging after one and two thirds through the treatmentOne to two intra-treatment Cone-beam CT scansOne intra-fraction cone-beam CT scan half-way through treatmentTypical one or two mid treatment cone-beam CTs

Imaging after treatmentYesNoYesYesNo
Patient (re-)positioning and IGRT

Follow-up

Follow up is performed in-house whenever possible in all institutions; the interval is most frequently every 3 months (table 9). Local tumor control is defined as tumor shrinkage or no tumor progression in serial imaging, with MRI as the preferable imaging modality. One institution (RSMC) uses routine FDG-PET imaging for evaluation of local tumor control. Pain is assessed in 4/5 institutions using either the Visual Analog Scale (UHW, UPMC, UVAMC) or NRS-11 (RSMC).
Table 9

Follow-up and response evaluation

UHWUPMCUofTUVAMCRSMC
Place of follow-upIn clinicIn clinicIn clinicIn clinicIn clinic

Definition of local controlNo progression on serial imaging.No progression on serial imaging.No progression on serial imaging.No progression on serial imaging.No progression on serial imaging.

Imaging modalities required for definition of local controlMRI if possibleMRI if possibleMRI if possibleMRI if possibleMRI/PET

System for pain scoringVisual analogue scaleVisual analogue scaleN/A unless of study then the Brief Pain InventoryVisual analogue scaleNRS-11

Frequency of FU examinationsEvery three months, every six months after 1 year1 month, then 3 months, then 6, 12, and then yearly.Every 2-3 months3 month intervals for the first yearEvery 3 months
Follow-up and response evaluation

Discussion

This survey observed strong agreement in terms of the treatment planning and treatment delivery aspects of spine radiosurgery. Especially safety and quality assurance of this novel treatment technique play a major role in the methods of all institutions. The following measures are considered as highly important for as safe-as-possible practice of spine radiosurgery. 1) Close cooperation between radiation oncologists and neurosurgeons especially in patients with epidural disease, spinal cord compression and instability; 2) Limitation of the target volume to maximum 3 vertebras; 3) Dedicated imaging protocols for target and organ-at-risk definition; 4) Anatomical target volume concepts with application of proper safety margins for the target volume and the spinal cord; 5) Highly conformal treatment planning, daily image-guidance, thorough patient immobilization and intra-fraction patient monitoring; 6) Close follow-up with repeated clinical and radiological response evaluation. In contrast, three major areas of uncertainty and disagreement were identified: 1) Indications and contra-indications for spine radiosurgery; 2) treatment dose and 3) tolerance dose of the spinal cord. These areas will be discussed more in detail.

Discussion with respect to Indication

Patient factors influencing indication for spine radiosurgery

Several prognostic scoring systems have been developed for overall survival after conventional, palliative radiotherapy for painful spine metastases [8,10,22] or metastatic spinal cord compression [23]. Recently, a recursive partitioning analysis (RPA) was reported for survival specific to spine SBRT [24]. The most favorable patients (Class 1, median OS of 21.1 months) were those with a time from primary diagnosis (TPD) > 30 months and a Karnofsky performance status (KPS) > 70, Class 2 was defined as those with a TPD > 30 months and KPS < 70 or a TPD < 30 months and age < 70 years (median OS of 8.7 months), and Class 3 was associated with the poorest outcomes and defined as TPD < 30 months and age > 70 years (median OS of 2.4 months). One could argue that spine radiosurgery would seem well indicated in patients with a longer life expectancy given that pain response of conventional doses is typically limited to 3 - 6 months (median duration of pain response) and multiple studies reported excellent pain control for a duration of 12 months after radiosurgery [12,13,25-27]. On the other hand, patients with short life expectancy could also benefit from spine radiosurgery; however, the rationale for radiosurgery would then be achievement of more rapid pain relief. For conventional radiotherapy, a mean pain response time of 3 weeks was reported by Van Der Linden et al. [28]. Ryu et al. and Chang et al. reported a slightly shorter median time to maximum pain relief of about 2 weeks such that even RPA class 3 patients could benefit from spine radiosurgery [12,25]. Whether this difference in pain relief reaches statistical significance needs to be demonstrated by a prospective trial. Until then, spine radiosurgery should be considered as a viable if not preferable option when rapid pain relief is required.

Tumor factors influencing indication for spine radiosurgery

Radiosurgical treatment of patients with epidural involvement is a major point of controversy. For tree institutions, epidural involvement was not a relevant factor in the decision making process for spine radiosurgery, whereas two institutions either required a clearance margin between the GTV and the spinal cord or preferred a surgical procedure prior to radiosurgery. Of note, the RTOG 0631 trial mandates a margin of 5 mm between the GTV and the spinal cord. This variation in indication is most likely explained by the risk of recurrence at the epidural space: three studies reported that 47 - 50% of all local failures after spine radiosurgery occur at the epidural space [12,27,29]. Sahgal et al. reported a trend towards local tumor recurrence if the GTV was within a distance of ≤1 mm to the spinal cord [30] and the minimum dose delivered to the target volume was shown as correlated with local tumor control [31]. A strategy to cope with epidural disease could be the application of fractionation schemes, which are adapted to the extent of epidural involvement [32]: single-fraction radiosurgery for targets with a clearance margin between the tumor and the spinal cord and fractionated radiosurgery if this clearance margin is violated. This fractionation could make use of basic radiobiology and deliver higher biological effective doses to the epidural tumor. However, the details regarding clearance margin and number of treatment fractions still have to be defined.

Dose-fractionation

As previously mentioned, no dose response has been established for conventional palliative radiotherapy with doses between 8 Gy in 1 fraction and 40 Gy in 20 fractions. One explanation could be that all tested doses are well below established thresholds from radical radiotherapy: e.g. even the "high dose" approach of 40 Gy in 20 fractions would result in tumor control of less than 5% for NSCLC [33]. This hypothesis is supported by three studies, which reported a significant dose response relationship for primary [17,31] and re-irradiation [34] spine radiosurgery. The Memorial Sloan-Kettering Cancer Center (MSMCC) group reported excellent local control of > 95% for a prescription dose of 24 Gy and a minimum dose of > 15.1 Gy; however, the results are based on a retrospective review of serially dose-escalated patients and require validation before conclusions can be drawn. For pain control as primary endpoint, Ryu et al. reported a lower prescription dose threshold of 14 Gy; this dose response was not statistically significant [25]. It is important to interpret all these treatment doses in the context of the target and OAR volumes, which were used in the specific trials. Clinical application of any dose specification without detailed knowledge and application of the respective target and OAR concept cannot be recommended. Centers in this study use a large rage of fractionations between single fraction to 10 fractions. Moreover, even within the single fraction treatment, the applied doses range between 16 Gy to 24 Gy. In the US, radiosurgery and stereotactic body radiotherapy are defined as treatment with maximum five fractions. In this study, one institution uses a 10 fraction approach, which does not fall under this definition. Nevertheless, we use the term radiosurgery even for this 10 fraction regimen because of two reasons: 1) the clinical and technical practice of the 10 fraction regimen is identical to the regimens using 1- 5 fractions; 2) using the LQ model, the biological effective dose of the 10 fraction regimen is expected to be at least equivalent to the 1- 5 fractions regimens. However, the limitations of the LQ model need to be considered for very high single fraction doses [35].

Tolerance dose of the spinal cord

The third area of uncertainty and disagreement is the tolerance dose of the spinal cord. There was agreement between 4/5 institutions that a planning organ-at-risk should be generated with a safety margin around the true spinal cord. However, this safety margin varied between 1 mm around the spinal cord to 2 mm around the spinal canal. The dosimteric parameter used as dose threshold varied between Dmax, D10, D0.1 cc and D2 cc. The closest agreement was observed for single fraction radiosurgery, where dose thresholds of 10 - 11 Gy are used. A very low incidence of myelopathy after spine radiosurgery has been described in the literature, despite dose escalation and hypo-fractionation. Ryu et al. observed a myelopathy in 1 out of 86 patients with a minimum follow-up of one year; these authors recommended a tolerance dose of 10 Gy as D10 [36]. Combined data from Stanford University Medical Center and University of Pittsburgh Medical Center reported an incidence of 5 out of 1075 patients, and it was recommended limiting the volume of spinal cord treated above an 8-Gy equivalent dose [37]. Sahgal et al. collected five cases of myelopathy and compared various dose volume parameters with 29 patients, who did not develop myelopathy [38]; all patients were treated with various radiosurgical fractionations. The thecal sack was delineated as the planning organ-at-risk volume for all cases and controls with centralized review of the DVH data. Doses were converted to 2 Gy-equivalent doses based on an α/β = 2 Gy to cope with variation of fractionation. The maximum point volume EQD2 Gy within the thecal sac significantly correlated with the risk of myelopathy as opposed to the larger volumes investigated (0.1 cc, 2 cc, and 5 cc). An EQD2 Gy threshold of 30 - 35 Gy was recommended for 1 - 5 fractions. In conventionally fractionated radiotherapy, the tolerance of the spinal cord is usually accepted between 45 - 50 Gy, despite that even a dose of 60 Gy results in a risk of myelopathy of only approximately 5% [39]. This disagreement between EQD2 Gy thresholds based on hypo-fractionation and thresholds based on conventionally fractionated radiotherapy has recently been confirmed by Daly et al. [40]. Further research is consequently required in this field as we do not yet understand the biologic ramifications of high dose per fraction on the normal tissues or tumor itself.

Conclusions

Strong agreement in the methods of spine radiosurgery was observed. In particular, similarities were observed with safety and quality assurance playing an important role in the methods of all institutions: cooperation between neurosurgeons and radiation oncologists in case selection, dedicated imaging for target- and organ-at-risk delineation, application of proper safety margins for the target volume and organs-at-risk, conformal planning and precise image-guided treatment delivery, and close clinical and radiological follow-up. In contrast, three major areas of uncertainty and disagreement were identified: 1) Indications and contra-indications for spine radiosurgery; 2) treatment dose and fractionation and 3) tolerance dose of the spinal cord. Further research in form of retrospective and especially prospective studies is required to refine spinal radiosurgery in terms of safety and efficacy.

Competing interests

This research was partially supported through an Elekta research grant with all institutions being members of the Elekta Spine Radiosurgery Research Consortium. This work and these data, however, are the intellectual property of the individual group members and their sponsoring institutions.

Authors' contributions

MG designed the study, collected the data and performed the data analysis. RAS participated in data collection and analysis. JCF, PDG, RK, JS, AS participated in data collection. All authors performed critical review of the manuscript and finally approved the manuscript.
  39 in total

Review 1.  Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.

Authors:  Stephen Lutz; Lawrence Berk; Eric Chang; Edward Chow; Carol Hahn; Peter Hoskin; David Howell; Andre Konski; Lisa Kachnic; Simon Lo; Arjun Sahgal; Larry Silverman; Charles von Gunten; Ehud Mendel; Andrew Vassil; Deborah Watkins Bruner; William Hartsell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

2.  Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment.

Authors:  Yvette M van der Linden; Judith J Lok; Elsbeth Steenland; Hendrik Martijn; Hans van Houwelingen; Corrie A M Marijnen; Jan Willem H Leer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

3.  Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases.

Authors:  Shari Damast; Jean Wright; Mark Bilsky; Meier Hsu; Zhigang Zhang; Michael Lovelock; Brett Cox; Joan Zatcky; Yoshiya Yamada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

Review 4.  Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes?

Authors:  Peter C Gerszten; Ehud Mendel; Yoshiya Yamada
Journal:  Spine (Phila Pa 1976)       Date:  2009-10-15       Impact factor: 3.468

5.  Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases.

Authors:  Samuel T Chao; Shlomo A Koyfman; Neil Woody; Lilyana Angelov; Sherry L Soeder; Chandana A Reddy; Lisa A Rybicki; Toufik Djemil; John H Suh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

6.  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.

Authors:  E Steenland; J W Leer; H van Houwelingen; W J Post; W B van den Hout; J Kievit; H de Haes; H Martijn; B Oei; E Vonk; E van der Steen-Banasik; R G Wiggenraad; J Hoogenhout; C Wárlám-Rodenhuis; G van Tienhoven; R Wanders; J Pomp; M van Reijn; I van Mierlo; E Rutten; J Leer; T van Mierlo
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

7.  A survey of stereotactic body radiotherapy use in the United States.

Authors:  Hubert Pan; Daniel R Simpson; Loren K Mell; Arno J Mundt; Joshua D Lawson
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

8.  Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery.

Authors:  Megan E Daly; Gary Luxton; Clara Y H Choi; Iris C Gibbs; Steven D Chang; John R Adler; Scott G Soltys
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-29       Impact factor: 7.038

9.  Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column: a review of 544 patients at Shizuoka Cancer Center Hospital.

Authors:  Masashi Mizumoto; Hideyuki Harada; Hirofumi Asakura; Takayuki Hashimoto; Kazuhisa Furutani; Haruko Hashii; Tatsuya Takagi; Hirohisa Katagiri; Mitsuru Takahashi; Tetsuo Nishimura
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

10.  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

Authors:  P Price; P J Hoskin; D Easton; D Austin; S G Palmer; J R Yarnold
Journal:  Radiother Oncol       Date:  1986-08       Impact factor: 6.280

View more
  11 in total

1.  A comparison of stereotactic body radiation therapy for metastases to the sacral spine and treatment of the thoracolumbar spine.

Authors:  Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; Jason P Sheehan; William H McAllister; Charles R Kersh
Journal:  J Radiosurg SBRT       Date:  2020

2.  SBRT planning for spinal metastasis: indications from a large multicentric study.

Authors:  Marco Esposito; Laura Masi; Margherita Zani; Raffaela Doro; David Fedele; Cristina Garibaldi; Stefania Clemente; Christian Fiandra; Francesca Romana Giglioli; Carmelo Marino; Laura Orsingher; Serenella Russo; Michele Stasi; Lidia Strigari; Elena Villaggi; Pietro Mancosu
Journal:  Strahlenther Onkol       Date:  2018-10-23       Impact factor: 3.621

Review 3.  Spinal metastases: From conventional fractionated radiotherapy to single-dose SBRT.

Authors:  Carlo Greco; Oriol Pares; Nuno Pimentel; Elizabeth Moser; Vasco Louro; Xavier Morales; Barbara Salas; Zvi Fuks
Journal:  Rep Pract Oncol Radiother       Date:  2015-04-18

4.  A multi-national report on methods for institutional credentialing for spine radiosurgery.

Authors:  Peter C Gerszten; Arjun Sahgal; Jason P Sheehan; Ronald Kersh; Stephanie Chen; John C Flickinger; Mubina Quader; Daniel Fahim; Inga Grills; John H Shin; Brian Winey; Kevin Oh; Reinhart A Sweeney; Matthias Guckenberger
Journal:  Radiat Oncol       Date:  2013-06-27       Impact factor: 3.481

5.  Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis.

Authors:  Matthias Guckenberger; Frederick Mantel; Peter C Gerszten; John C Flickinger; Arjun Sahgal; Daniel Létourneau; Inga S Grills; Maha Jawad; Daniel K Fahim; John H Shin; Brian Winey; Jason Sheehan; Ron Kersh
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

6.  Variability in spine radiosurgery treatment planning - results of an international multi-institutional study.

Authors:  André Toussaint; Anne Richter; Frederick Mantel; John C Flickinger; Inga Siiner Grills; Neelam Tyagi; Arjun Sahgal; Daniel Letourneau; Jason P Sheehan; David J Schlesinger; Peter Carlos Gerszten; Matthias Guckenberger
Journal:  Radiat Oncol       Date:  2016-04-18       Impact factor: 3.481

7.  Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial.

Authors:  Tanja Sprave; Stefan Ezechiel Welte; Thomas Bruckner; Robert Förster; Tilman Bostel; Ingmar Schlampp; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  Trials       Date:  2018-01-22       Impact factor: 2.279

Review 8.  The role of radiation therapy in bone metastases management.

Authors:  Francesca De Felice; Andrea Piccioli; Daniela Musio; Vincenzo Tombolini
Journal:  Oncotarget       Date:  2017-04-11

Review 9.  Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.

Authors:  Michael Huo; Arjun Sahgal; David Pryor; Kristin Redmond; Simon Lo; Matthew Foote
Journal:  Surg Neurol Int       Date:  2017-02-20

Review 10.  Radioresistance of Brain Tumors.

Authors:  Kevin Kelley; Jonathan Knisely; Marc Symons; Rosamaria Ruggieri
Journal:  Cancers (Basel)       Date:  2016-03-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.